ArticleFrontiers in cardiovascular medicine2023
Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- A systematic review and meta-analysis of the use of drug-coated balloon angioplasty for treatment of both de novo and in-stent coronary chronic total occlusions.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Clinical outcomes of drug-coated balloonsCardiovascular diagnosis and therapy · 2026Article
- Clinical application and expansion of paclitaxel-coated balloons in coronary atherosclerotic disease.World journal of cardiology · 2026Review
- Feasibility and safety of only DCB approach in consecutive patients undergoing contemporary CTO PCI; the all-comers DCB study.Frontiers in cardiovascular medicine · 2026Article
- Blended Coronary Revascularization with Drug-Coated Balloon and Drug-Eluting Stent: A Narrative Review on Rationale, Clinical Evidence, and Future Perspectives.Journal of clinical medicine · 2025Review
- Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand.Journal of clinical medicine · 2025Review
- Drug-coated balloon angioplasty for chronic total coronary occlusions. Blended strategies: the best of two worlds.International journal of cardiology. Heart & vasculature · 2025Article
- Long-Term Effectiveness of a Stent-Less Strategy With Drug Coated Balloon in Coronary Artery Disease: 3-Year Follow-Up of a Prospective All-Comers Observational Study.Clinical cardiology · 2025Observational
- Drug-Coated Balloons in All-Comer Population-Are We There Yet?Journal of clinical medicine · 2025Review
- Leaving Nothing Behind: Expanding the Clinical Frontiers of Drug-Coated Balloon Angioplasty in Coronary Artery Disease.Journal of cardiovascular development and disease · 2025Review
- Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.Cardiology journal · 2025Review
- Contemporary Use of Drug-Coated Balloons for Coronary Angioplasty: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Retrospective analysis of the drug-coated balloon-only strategy for chronic total occlusion coronary lesions.Journal of thoracic disease · 2024Article
- Drug-Coated Balloon Angioplasty in Patients Undergoing Complex Percutaneous Coronary Intervention.JACC. Asia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data on drug-coated balloons (DCB) for Methods: We compared the outcomes of less DES strategy (DCB alone or combined with DES) and DES-only strategy in treating Results: Of the 591 eligible patients consecutively enrolled between January 2015 and December 2019, 281 (290 lesions) were treated with DCB (DCB-only or combined with DES) and 310 (319 lesions) with DES only. In the DCB group, 147 (50.7%) lesions were treated using DCB-only, and the bailout stenting rate was relatively low (3.1%). The average stent length per lesion in the DCB group was significantly shorter compared with the DES-only group (21.5 ± 25.5 mm vs. 54.5 ± 26.0 mm, Conclusion: Percutaneous coronary intervention with DCB is a potential "stent-less" therapy for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.